Findings demonstrate that long-acting cabotegravir and rilpivirine maintain virological control in people with HIV, suggesting effective ART use in practice.
LA CAB and RPV achieve plasma exposures consistent with clinical trials, maintaining virological suppression despite pharmacokinetic variability. Intracellular accumulation, especially of RPV, may contribute to sustained virological control. These findings support the use of LA CAB/RPV as a robust ART option in real-world clinical practice.
No takes yet. Share an insight, caveat, or question.
Ferrara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: